Finance

Lists
Q2 2026 earnings • released • EPS beat +18.17% • Revenue beat +7.44%
See results
ARGX:NASDAQ
argenx SE - ADR
$918.22
-0.69%
(-6.38) 1D
Jul 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARGX...
Open
$935.00
High
$935.88
Low
$910.19
Mkt. cap
56.50B
Avg. vol.
355.33K
Volume
0.00
P/E ratio
34.89
52-wk high
$953.58
52-wk low
$587.37
EPS
$26.32
Beta
0.45
Shares outstanding
62.56M
No. of employees
2K
Open
$935.00
High
$935.88
Low
$910.19
Mkt. cap
56.50B
Avg. vol.
355.33K
Volume
0.00
P/E ratio
34.89
52-wk high
$953.58
52-wk low
$587.37
EPS
$26.32
Beta
0.45
Shares outstanding
62.56M
No. of employees
2K
News stories
From sources across the web
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
CEO-
Employees1.86K
Founded2008
Headquarters-
SectorBiotechnology
Websiteargenx.com
Analyst ratings
Based on 21 analysts giving stock ratings to ARGX in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for ARGX in the last 3 months.
Highest
Current $918.22
$1,350.00 (+47.02%)
Average
$1,073.50 (+16.91%)
Lowest
$850.00 (-7.43%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Gordon CFA
Barclays
Buy
Maintained
$950.00
+3.5%
07/24/2026
Unknown Analyst
Wedbush
Buy
Maintained
$1,000.00
+8.9%
07/24/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$1,200.00
+30.7%
07/24/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$1,037.00
+12.9%
07/24/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$1,065.00
+16%
07/24/2026
Derek Archila
Wells Fargo
Buy
Maintained
$1,350.00
+47%
07/23/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$940.00
+2.4%
07/24/2026
Jason Butler
Citizens JMP
Buy
Maintained
$932.00
+1.5%
07/24/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$1,088.00
+18.5%
07/23/2026
Samantha Semenkow
Citi
Buy
Maintained
$1,203.00
+31%
07/24/2026
Luca Issi
RBC Capital
Buy
Reiterated
$1,025.00
+11.6%
07/23/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
07/23/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$1,135.00
+23.6%
07/21/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$1,146.00
+24.8%
07/21/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$1,255.00
+36.7%
06/29/2026
Unknown Analyst
Jefferies
Buy
Maintained
$1,013.00
+10.3%
06/25/2026
David Nierengarten
Wedbush
Buy
Maintained
$1,000.00
+8.9%
06/24/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
06/24/2026
Myles Minter
William Blair
Buy
Maintained
-
-
06/24/2026
Unknown Analyst
William O'Neil
Buy
Initiated
-
-
06/08/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
$1,059.00
+15.3%
05/15/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$1,075.00
+17.1%
05/11/2026
Xian Deng
UBS
Hold
Maintained
$850.00
-7.4%
05/08/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
$867.00
-5.6%
02/27/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
$910.00
-0.9%
02/26/2026
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$7.32 / $6.19
+18.17%beat
Revenue / Est. (USD)
1.54B / 1.43B
+7.44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.15B
1.31B
1.31B
1.54B
Cost of goods sold
465.08M
521.40M
564.00M
631.00M
Cost of revenue
465.08M
521.40M
564.00M
631.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336.29M
429.62M
355.00M
417.00M
Operating expense
336.29M
429.62M
355.00M
417.00M
Total operating expenses
801.37M
951.02M
919.00M
1.05B
Operating income
349.97M
359.56M
394.00M
493.00M
Other non operating income
-
-907.00K
-
-1.00M
EBT including unusual items
386.05M
403.29M
426.00M
531.00M
EBT excluding unusual items
386.05M
391.71M
426.00M
531.00M
Income tax expense
41.80M
-129.66M
60.00M
59.00M
Effective tax rate
10.83%
-32.15%
14.08%
11.11%
Other operating expenses
-
-
-
-
Net income
344.26M
532.95M
366.00M
472.00M
Net profit margin
29.90%
40.67%
27.88%
30.63%
Earnings per share
5.18
8.02
5.52
7.32
Interest and investment income
42.70M
44.95M
44.00M
48.00M
Interest expense
-993.00K
-
-1.00M
-1.00M
Net interest expenses
41.71M
44.95M
43.00M
47.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
350.35M
361.38M
395.82M
501.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer